Breast cancer in women using digoxin: Tumor characteristics and relapse risk

Breast Cancer Research

Volumn 15, Issue 1, 2013, Pages

  Biggar, Robert J ^a,b   Andersen, Elisabeth W ^a   Kroman, Niels ^c   Wohlfahrt, Jan ^a   Melbye, Mads ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; ESTROGEN RECEPTOR; TAMOXIFEN; AROMATASE INHIBITOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; TUMOR VOLUME; BREAST NEOPLASMS; CHEMICALLY INDUCED; DENMARK; HEART DISEASES; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ADULT; AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; DENMARK; DIGOXIN; FEMALE; HEART DISEASES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RISK FACTORS; TAMOXIFEN;

EID: 84873957270     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3386     Document Type: Article

References (33)

1. McDonough AA, Velotta JB, Schwinger RH, Philipson KD, Farley RA. The cardiac sodium pump: structure and function. Basic Res Cardiol 2002, 97(Suppl 1):I19-24.
2. Biggar RJ. Molecular pathways: digoxin use and estrogen-sensitive cancers--risks and possible therapeutic implications. Clin Cancer Res 2012, 18:2133-2137. 10.1158/1078-0432.CCR-11-1389, 22368159.
3. Ahern TP, Lash TL, Sørensen HT, Petersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case control study. Breast Cancer Res 2008, 10:R102. 10.1186/bcr2205, 2656898, 19055760.
4. Biggar RJ, Wohlfahrt J, Oudin A, Hjuler T, Mads M. Digoxin use and the risk of breast cancer in women. J Clin Oncol 2011, 29:2165-2170. 10.1200/JCO.2010.32.8146, 21422417.
5. Biggar RJ, Wohlfahrt J, Melbye M. Digitalis use and cancers of the corpus uteri, ovary and cervix. Int J Cancer 2012, 131:716-721. 10.1002/ijc.26424, 21913187.
6. Holmberg L, Anderson H, HABITS steering and data monitoring committees HABITS (hormonal replacement therapy after breast cancer-is it safe?) A randomized comparison: trial stopped. Lancet 2004, 363:453-455. 10.1016/S0140-6736(04)15493-7, 14962527, HABITS steering and data monitoring committees.
7. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J, HABITS Study Group Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. JNCI 2008, 100:475-482. 10.1093/jnci/djn058, 18364505, HABITS Study Group.
8. Colditz GA, Baer HJ, Tamimi RM. Breast Cancer. Cancer Epidemiology and Prevention 2006, 995-1012. New York: Oxford University Press, Inc, Schottenfeld D, Fraumeni JF Jr.
9. Rivera-Guevara C, Camacho J. Tamoxifen and its new derivatives in cancer research. Recent Pat Anticancer Drug Discov 2011, 6:237-245. 10.2174/157489211795328486, 21247404.
10. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011, 125:13-22. 10.1016/j.jsbmb.2011.02.001, 3104073, 21335088.
11. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, Christiansen P, Mouridsen HT, Danish Breast Cancer Cooperative Group The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008, 47:506-524. 10.1080/02841860802059259, 18465317, Danish Breast Cancer Cooperative Group.
12. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997, 44:445-448.
13. Lokkegaard E, Lidegaard O, Moller LN, Agger C, Andreasen AH, Jorgensen T. Hormone replacement therapy in Denmark, 1995-2004. Acta Obstet Gynecol Scand 2007, 86:1342-1351. 10.1080/00016340701505523, 17963062.
14. Cox DR. Regression models and life-tables (with discussion). J Royal Statistical Society, Series B 1972, (34):187-220.
15. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
16. Little RJA, Rubin DB. Statistical Analysis with Missing Data 2002, Hoboken, NJ: Wiley, 2.
17. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350:1047-1059. Collaborative Group on Hormonal Factors in Breast Cancer.
18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397, Writing Group for the Women's Health Initiative Investigators.
19. Chlebowski RT, Anderson GL. Progestins and recurrence in breast cancer survivors. J Natl Cancer Inst 2005, 97:471-472. 10.1093/jnci/dji100, 15812065.
20. Chen W, Petitti D, Geiger A. Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer 2005, 93:392-398. 10.1038/sj.bjc.6602701, 2361586, 16106246.
21. Cheek J, Lacy J, Toth-Fejel S, Morris K, Calhoun K, Pommier RF. The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 2002, 137:1015-1019. 10.1001/archsurg.137.9.1015, 12215151.
22. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. ¬Obstet Gynecol 1995, 85:11-17.
23. Newcomb PA, Egan KM, Trentham-Dietz A, Titus-Ernstoff L, Baron JA, Hampton JM, Stampfer MJ, Willett WC. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:864-871. 10.1158/1055-9965.EPI-07-0610, 2780320, 18381475.
24. Alfred DC, Anderson SJ, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE, Costantino JP, Land SR, Wolmark N. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP Protocol B-24. J Clin Oncol 2012, 30:1268-1273. 10.1200/JCO.2010.34.0141, 22393101.
25. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev 2003, 4:157-173. 10.1046/j.1467-789X.2003.00108.x, 12916817.
26. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010, 15:556-565. 10.1634/theoncologist.2009-0285, 3227989, 20507889.
27. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 2003, 95:1467-1476. 10.1093/jnci/djg060, 14519753.
28. Majed B, Dozol A, Ribassin-Majed L, Senouci K, Asselain B. Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association. Breast Cancer Res Treat 2011, 126:729-738. 10.1007/s10549-010-1153-z, 20872242.
29. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Fetting J, Davidson NE. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 2012, 118:5937-5946. 10.1002/cncr.27527, 3586227, 22926690.
30. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010, 123:627-635. 10.1007/s10549-010-0990-0, 20571870.
31. Ewertz M, Jensen MB, Gunnarsdóttir K, Højris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011, 29:25-31. 10.1200/JCO.2010.29.7614, 21115856.
32. de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Late relapse typically assoc with ER+ disease. J Clin Oncol 1996, 14:2738-2746.
33. Schelbert KB. Comorbidities of obesity. Prim Care 2009, 36:271-285. 10.1016/j.pop.2009.01.009, 19501243.